Breaking News Instant updates and real-time market news.

MAR

Marriott

$78.52

0.44 (0.56%)

, HOT

Starwood

13:42
11/28/16
11/28
13:42
11/28/16
13:42

Marriott brand chief: Combining loyalty plans 'no trivial thing,' Bloomberg says

Speaking in a Bloomberg interview published Monday, Marriott (MAR) global brand officer Tina Edmundson gave no indication that the company plans to trim its brand collection, which has now grown to 30 after its acquisition of Starwood Hotels. The publication notes that details on combining the companies' loyalty programs are "still TBD," adding that Marriott is "not anywhere near" revealing terms of the joint program yet, with Edmundson remarking that developing such a plan is "no trivial thing." Note that analysts have highlighted the merger as a potential point of friction to American Express' (AXP) co-brand deal with Starwood. Reference Link

MAR

Marriott

$78.52

0.44 (0.56%)

HOT

Starwood

AXP

American Express

$72.32

-0.54 (-0.74%)

  • 29

    Nov

MAR Marriott
$78.52

0.44 (0.56%)

11/28/16
11/28/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AbbVie (ABBV) downgraded to Neutral from Buy at Citi. 2. Citi (C), Wells Fargo (WFC), and Regions Financial (RF) were downgraded to Hold from Buy at Jefferies with analyst Ken Usdin citing valuation. 3. Hilton (HLT) and Marriott (MAR) were downgraded to Hold from Buy at Evercore ISI. 4. H&R Block (HRB) downgraded to Sell from Neutral at BTIG with analyst Mark Palmer noting that President-elect Trump has said he wants to put H&R Block out of business by simplifying the tax code. 5. Tupperware Brands (TUP) downgraded to Sell from Neutral at B. Riley with analyst Linda Bolton Weiser saying the stock has not moved lower to reflect post-election currency devaluations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/28/16
EVER
11/28/16
DOWNGRADE
Target $80
EVER
Hold
Marriott downgraded to Hold from Buy at Evercore ISI
Evercore ISI analysts led by Steve Sakwa downgraded Kilroy Realty to Hold on valuation and maintained its price target of $80.
11/18/16
DBAB
11/18/16
INITIATION
Target $80
DBAB
Hold
Marriott reinstated with a Hold at Deutsche Bank
Deutsche Bank analyst Carlo Santarelli reinstated Marriott with a Hold rating and $80 price target.
10/25/16
NOMU
10/25/16
DOWNGRADE
NOMU
Neutral
Hyatt, Host Hotels downgraded to Neutral at Nomura
As previously reported, Nomura analyst Harry Curtis downgraded Hyatt (H) and Host Hotels (HST), both to Neutral from Buy, saying that their multiples are unlikely to expand this late in the lodging cycle. Industry RevPAR growth is expected to be roughly 2.5%, or possibly lower, in the second half of 2016 and should remain at current levels with no meaningful change in the supply/demand balance, and asset-heavier companies like Host and Hyatt generate little EBITDA growth at those levels due to cost pressures, Curtis tells investors. The analyst, who prefers asset-light business models, keeps Buy ratings on Hilton (HLT) and Marriott (MAR). Curtis lowered his price target on Host Hotels to $16 from $19 and cut his target on Hyatt to $54 from $59.
HOT Starwood

05/04/16
ADAM
05/04/16
DOWNGRADE
ADAM
Hold
Starwood downgraded to Hold from Buy at Canaccord
10/04/16
OPCO
10/04/16
NO CHANGE
Target $22
OPCO
Outperform
Oppenheimer remains bullish on Interval Leisure ahead of results
Oppenheimer analyst Ian Zaffino expects Interval Leisure (IILG) to report "solid" Q3 results. The analyst says the company appears to have momentum, noting that it has completed an upsized securitization, the Vistana integration has been smooth, defaults have been stable and the standstill agreement with Starwood's (HOT) and Marriott's (MAR) loyalty programs eliminates near-term uncertainty and paves the way for future M&A. He reiterates an Outperform rating and $22 price target on Interval Leisure's shares.
06/30/16
06/30/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on the today's top five analyst upgrades with this list compiled by The Fly: 1. Priceline (PCLN) upgraded to Overweight from Equal Weight at Morgan Stanley by analysts led by Brian Nowak, who raised his price target to $1,525 from $1,330. The analyst sees improving ad efficiency driving increased profitability and material market share gains in alt. accommodations. Nowak sees a more rational ad environment resulting in margin improvement and raised 2017 room nights by 2%, with alt. accommodations set to grow 34% 2015-2018 CAGR, driving bookings growth to 28.5%. 2. Motorola Solutions (MSI) upgraded to Buy from Neutral at Goldman by analyst Matthew Cabral after assuming primary coverage of the shares. The company's renewed focus on revenue growth and spending management is a positive shift in strategy, Cabral tells investors in a research note. He believes the shares at current levels offer a compelling entry point. Cabral raised his price target for Motorola Solutions to $81 from $74. The firm also upgraded Nokia (NOK) to Buy from Neutral. 3. Parker-Hannifin (PH) upgraded to Outperform from Market Perform at Wells Fargo by analyst Andrew Casey, citing the recent pullback in shares, low investor expectations and positive fluid power distributor channel checks. The analyst keeps a $117-$120 price target range for the shares. 4. Marriott (MAR) upgraded to Buy from Hold at Evercore ISI by analyst Rich Hightower, who trimmed his price target to $75 from $76. The analyst has now fully incorporated Starwood's (HOT) numbers into the model and said weakness following Brexit has created a buying opportunity. 5. Yamana Gold (AUY) upgraded to Outperform from Neutral at Credit Suisse by analyst Anita Soni, who raised her price target to $6.50 from $4.50 in conjunction with an increased gold price forecast. The firm has increased its gold price forecast to a peak of $1,500 in Q1 2017. The analyst also upgraded Silver Wheaton (SLW) to Outperform from Neutral and IAMGOLD (IAG) to Neutral from Sell. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/04/16
ADAM
05/04/16
DOWNGRADE
Target $86
ADAM
Hold
Starwood downgraded to Hold at Canaccord
As reported previously, Canaccord downgraded Starwood (HOT) to Hold from Buy. The firm cited the company's pending merger with Marriott (MAR) and the unlikeliness of Starwood shares outperforming Marriott prior to the closing. Canaccord lowered its price target to $86 from $88 on Starwood shares.
AXP American Express
$72.32

-0.54 (-0.74%)

11/18/16
11/18/16
INITIATION
Target $62

Underweight
Discover initiated with an Underweight at Stephens
As previously reported, Stephens analyst Vincent Caintic started Discover (DFS) with an Underweight rating and $62 price target, citing shrinking margins as American Express (AXP) ramps up rewards to maintain share, credit costs normalizing higher likely making Discover's shares range bound, and personal lending competition. The analyst also started American Express with an Underweight rating.
11/18/16
11/18/16
INITIATION
Target $40

Overweight
Synchrony initiated with an Overweight at Stephens
As previously reported, Stephens analyst Vincent Caintic started Synchrony (SYF) with an Overweight rating and $40 price target, citing $5B excess capital that allows Synchrony to buy back 20% of company once capital return is deregulated, industry retail share weakness, and revenue growth. The analyst also started American Express (AXP) and Discover (DFS) with an Underweight rating.
11/18/16
11/18/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cisco (CSCO) coverage resumed with a Hold at Stifel. 2. UPS (UPS) was initiated with an Outperform at BMO Capital while the firm initiated FedEx (FDX) with a Market Perform. 3. Synchrony (SYF) was initiated with an Overweight at Stephens. The firm also initiated American Express (AXP) and Discover (DFS) with an Underweight. 4. American Airlines (AAL), Delta Air Lines (DAL), Southwest (LUV) and Allegiant Travel (ALGT) were initiated with a Buy at Citi while the firm initiated JetBlue (JBLU), United Continental (UAL), Alaska Air (ALK), and Hawaiian Holdings (HA) with a Neutral. 5. Juniper (JNPR) coverage resumed at Stifel. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/18/16
11/18/16
INITIATION
Target $65

Underweight
American Express initiated with an Underweight at Stephens
As previously reported, Stephens analyst started American Express (AXP) with an Underweight rating and $65 price target, citing rising rates, shrinking markets as American Express ramps up rewards to maintain share, and the risk to 2017 EPS guidance. The analyst expects competition from bank peers, such as JPMorgan (JPM) and Citi (C), to continue to pressure American Express' earnings.

TODAY'S FREE FLY STORIES

SBUX

Starbucks

$57.21

-1.3 (-2.22%)

17:09
12/04/16
12/04
17:09
12/04/16
17:09
Conference/Events
Starbucks to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CS

Credit Suisse

$13.39

-0.34 (-2.48%)

17:03
12/04/16
12/04
17:03
12/04/16
17:03
Conference/Events
Credit Suisse to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.40

0.135 (0.67%)

, SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

17:02
12/04/16
12/04
17:02
12/04/16
17:02
Hot Stocks
Takeda Pharma, Seattle Genetics reports Phase 3 ADCETRIS data »

Takeda Pharmaceutical…

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.40

0.135 (0.67%)

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CGEN

Compugen

$5.95

0.1 (1.71%)

16:59
12/04/16
12/04
16:59
12/04/16
16:59
Conference/Events
Compugen to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

QURE

uniQure

$5.68

-0.31 (-5.18%)

16:56
12/04/16
12/04
16:56
12/04/16
16:56
Hot Stocks
uniQure reports data on AMT-060 in hemophilia B »

uniQure announced new and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 08

    Dec

RGLS

Regulus

$2.50

0.1 (4.17%)

16:53
12/04/16
12/04
16:53
12/04/16
16:53
Conference/Events
Regulus to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 14

    Dec

PBI

Pitney Bowes

$14.63

0.1 (0.69%)

16:52
12/04/16
12/04
16:52
12/04/16
16:52
Conference/Events
Pitney Bowes to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

16:43
12/04/16
12/04
16:43
12/04/16
16:43
Hot Stocks
Seattle Genetics reports Phase 1b vadastuximab talirine data, plans Ph. 2 trial »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

NVS

Novartis

$68.17

0.42 (0.62%)

16:38
12/04/16
12/04
16:38
12/04/16
16:38
Hot Stocks
Novartis reports Phase 2 SEG101 data »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PFE

Pfizer

$31.63

0.17 (0.54%)

16:33
12/04/16
12/04
16:33
12/04/16
16:33
Hot Stocks
Pfizer reports Phase 2 glasdegib data »

Pfizer announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

EKSO

Ekso Bionics

$4.27

-0.11 (-2.51%)

16:30
12/04/16
12/04
16:30
12/04/16
16:30
Conference/Events
Ekso Bionics to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ADSK

Autodesk

$70.57

1.35 (1.95%)

16:24
12/04/16
12/04
16:24
12/04/16
16:24
Conference/Events
Autodesk to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 09

    Jan

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

16:23
12/04/16
12/04
16:23
12/04/16
16:23
Hot Stocks
Seattle Genetics reports Phase 2 ADCETRIS lymphoma data, says discontinues trial »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

FTI

FMC Technologies

$35.60

0.9 (2.59%)

, TKPPY

Technip

$17.80

0.45 (2.59%)

16:21
12/04/16
12/04
16:21
12/04/16
16:21
Conference/Events
Technip to host special shareholder meeting »

Special Shareholder…

FTI

FMC Technologies

$35.60

0.9 (2.59%)

TKPPY

Technip

$17.80

0.45 (2.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

TKPPY

Technip

$17.80

0.45 (2.59%)

, FTI

FMC Technologies

$35.60

0.9 (2.59%)

16:14
12/04/16
12/04
16:14
12/04/16
16:14
Conference/Events
FMC Technologies to host special shareholder meeting »

Special Shareholder…

TKPPY

Technip

$17.80

0.45 (2.59%)

FTI

FMC Technologies

$35.60

0.9 (2.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

16:04
12/04/16
12/04
16:04
12/04/16
16:04
Hot Stocks
Alnylam reports interim Phase 1 data on fitusiran »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADRO

Aduro Biotech

$10.80

0.25 (2.37%)

16:01
12/04/16
12/04
16:01
12/04/16
16:01
Hot Stocks
Aduro Biotech reports presentation of BION-1301 data »

Aduro Biotech announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIL

Trillium Therapeutics

$6.70

-0.5 (-6.94%)

15:59
12/04/16
12/04
15:59
12/04/16
15:59
Hot Stocks
Trillium Therapeutics reports presentation of TTI-621 data »

Trillium Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

BLUE

bluebird bio

$69.75

1.1 (1.60%)

15:47
12/04/16
12/04
15:47
12/04/16
15:47
Hot Stocks
bluebird bio reports new data from HGB-205 study of LentiGlobin »

bluebird bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLCM

Bellicum Pharmaceuticals

$18.72

1.74 (10.25%)

15:43
12/04/16
12/04
15:43
12/04/16
15:43
Hot Stocks
Bellicum Pharmaceuticals reports updated data from BPX-501 study »

Bellicum Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

15:39
12/04/16
12/04
15:39
12/04/16
15:39
Hot Stocks
Alnylam reports Phase 1 givosiran data, says plans Phase 3 study late 2017 »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$31.63

0.17 (0.54%)

, ONCE

Spark Therapeutics

$50.01

0.27 (0.54%)

15:32
12/04/16
12/04
15:32
12/04/16
15:32
Hot Stocks
Spark Therapeutics, Pfizer report updated preliminary data on SPK-9001 »

Spark Therapeutics (ONCE)…

PFE

Pfizer

$31.63

0.17 (0.54%)

ONCE

Spark Therapeutics

$50.01

0.27 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 04

    Dec

  • 06

    Dec

  • 06

    Dec

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

15:26
12/04/16
12/04
15:26
12/04/16
15:26
Conference/Events
Seattle Genetics to hold an investor reception »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$27.20

-0.1 (-0.37%)

15:21
12/04/16
12/04
15:21
12/04/16
15:21
Conference/Events
Roche to hold an analyst meeting »

Analyst Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

15:17
12/04/16
12/04
15:17
12/04/16
15:17
Hot Stocks
Juno Therapeutics reports Phase 1 data on JCAR014 »

Juno Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.